An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as Firstline Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Project: Research

Project Details

Project Description

NMA HREC Reference Number: 69122
NMA SSA Reference Number: SSA/69122/MonH-2021-249977(v1)
Monash Health Reference: RES-20-0000-786A
StatusActive
Effective start/end date10/12/209/12/25

Keywords

  • treatment safety
  • treatment efficacy
  • renal cancer
  • phase 3 study